Episode Details
Back to EpisodesPoolbeg’s Big Biotech Moment? First Patient Dosed Ahead of Key POLB 001 Data
Episode 2445
Published 2 months, 2 weeks ago
Description
Watch on YouTube
Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL clinical trial, marking the start of a key execution phase for its CRS prevention programme. With UCLH activated, further sites expected, interim data targeted for summer 2026 and partnering discussions ongoing, investors will be watching whether clinical progress can validate the programme’s claimed commercial potential.